Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • NCE Meeting Abstracts
  • AAP Policy
  • Supplements
  • Multimedia
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • NCE Meeting Abstracts
  • AAP Policy
  • Supplements
  • Multimedia
  • Subscribe
  • Alerts
  • Careers
American Academy of Pediatrics
ELECTRONIC ARTICLE

Montelukast, a Leukotriene Receptor Antagonist, for the Treatment of Persistent Asthma in Children Aged 2 to 5 Years

Barbara Knorr, Luis M. Franchi, Hans Bisgaard, Jan Hendrik Vermeulen, Peter LeSouef, Nancy Santanello, Theresa M. Michele, Theodore F. Reiss, Ha H. Nguyen and Donna L. Bratton
Pediatrics September 2001, 108 (3) e48; DOI: https://doi.org/10.1542/peds.108.3.e48
Barbara Knorr
From the Departments of Pulmonary-Immunology, Epidemiology, and Biostatistics, Merck Research Laboratories, Rahway, New Jersey and West Point, Pennsylvania;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis M. Franchi
Pediatric Pulmonary Service, Instituto de Salud del Niño, Lima, Peru;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Bisgaard
Paediatric Department, Rigshospitalet, Copenhagen, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Hendrik Vermeulen
101 Panorama Medical Clinic, South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter LeSouef
Department of Paediatrics, Children's Hospital Medical Centre, Perth, Australia; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Santanello
From the Departments of Pulmonary-Immunology, Epidemiology, and Biostatistics, Merck Research Laboratories, Rahway, New Jersey and West Point, Pennsylvania;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa M. Michele
From the Departments of Pulmonary-Immunology, Epidemiology, and Biostatistics, Merck Research Laboratories, Rahway, New Jersey and West Point, Pennsylvania;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theodore F. Reiss
From the Departments of Pulmonary-Immunology, Epidemiology, and Biostatistics, Merck Research Laboratories, Rahway, New Jersey and West Point, Pennsylvania;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ha H. Nguyen
From the Departments of Pulmonary-Immunology, Epidemiology, and Biostatistics, Merck Research Laboratories, Rahway, New Jersey and West Point, Pennsylvania;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna L. Bratton
National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • Place of Montelukast in the Management of Persistent Asthma
    Dr S K Agarwal
    Published on: 22 February 2002
  • Published on: (22 February 2002)
    Place of Montelukast in the Management of Persistent Asthma
    • Dr S K Agarwal, Head, Department of Chest Diseases,

    Available preventive therapies for persistent asthma include inhaled corticosteroids, sodium chromoglycate, oral leukotrienes and oral theophyllines. Among these agents, inhaled corticosteroids are the most effective because of their broad spectrum of anti-inflammatory activity. Inspite of this, the use of inhaled corticosteroids in asthma management are under prescribed by physicians and/or underused by patients.

    ...
    Show More

    Available preventive therapies for persistent asthma include inhaled corticosteroids, sodium chromoglycate, oral leukotrienes and oral theophyllines. Among these agents, inhaled corticosteroids are the most effective because of their broad spectrum of anti-inflammatory activity. Inspite of this, the use of inhaled corticosteroids in asthma management are under prescribed by physicians and/or underused by patients.

    There is a high rate of adherence with oral montelukast treatment. Montelukast has rapid onset of action in patients with asthma, which may promote adherence when treatment is initiated. Indeed, there appears to be a general consensus that oral admistration is an important advantage of the antileukotrienes.However, a recent study(1) found a marginal utility of montelukast in the management persistent asthma where the oral drug was given for 1 year.

    References:1. Mathison, DA and Koziol,JA. Marginal Utility of Montelukast for Persistent Asthma. Chest;121:334-337.

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 108, Issue 3
1 Sep 2001
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Montelukast, a Leukotriene Receptor Antagonist, for the Treatment of Persistent Asthma in Children Aged 2 to 5 Years
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
Request Permissions
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Montelukast, a Leukotriene Receptor Antagonist, for the Treatment of Persistent Asthma in Children Aged 2 to 5 Years
Barbara Knorr, Luis M. Franchi, Hans Bisgaard, Jan Hendrik Vermeulen, Peter LeSouef, Nancy Santanello, Theresa M. Michele, Theodore F. Reiss, Ha H. Nguyen, Donna L. Bratton
Pediatrics Sep 2001, 108 (3) e48; DOI: 10.1542/peds.108.3.e48

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Montelukast, a Leukotriene Receptor Antagonist, for the Treatment of Persistent Asthma in Children Aged 2 to 5 Years
Barbara Knorr, Luis M. Franchi, Hans Bisgaard, Jan Hendrik Vermeulen, Peter LeSouef, Nancy Santanello, Theresa M. Michele, Theodore F. Reiss, Ha H. Nguyen, Donna L. Bratton
Pediatrics Sep 2001, 108 (3) e48; DOI: 10.1542/peds.108.3.e48
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • APPENDIX
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach
  • Montelukast moderately decreased asthma symptoms in children with persistent asthma
  • Montelukast for Young Children with Asthma
  • Google Scholar

More in this TOC Section

  • Treatment of Attention-Deficit/Hyperactivity Disorder: Overview of the Evidence
  • Incidence of Cranial Asymmetry in Healthy Newborns
  • Factors That Influence Receipt of Recommended Preventive Pediatric Health and Dental Care
Show more ELECTRONIC ARTICLE

Similar Articles

Keywords

  • asthma
  • cysteinyl leukotrienes
  • leukotriene receptor antagonist
  • montelukast
  • preschool children
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Licensing Information
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • RSS Feeds
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2019 American Academy of Pediatrics